Back to Search Start Over

Data from Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma

Authors :
Lewis R. Roberts
Martin E. Fernandez-Zapico
Vijay H. Shah
Eric Chevet
Snorri S. Thorgeirsson
Ju-Seog Lee
Tao Song
Dehai Wu
Shaoqing Wang
Hassan M. Shaleh
Dongye Yang
Yong Fang
Yichun Chen
Abdul M. Oseini
Bubu A. Banini
Chunling Hu
Shaoshan Han
Catherine D. Moser
Michael K. Asiedu
Mengtao Zhou
Roongruedee Chaiteerakij
Alexander G. Miamen
Luciana L. Almada
Renzo E. Vera
Paola A. Romecin
Ezequiel J. Tolosa
Eriko Iguchi
Renumathy Dhanasekaran
Ikuo Nakamura
Gang Chen
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in this disease setting. Here, we report a novel role for sulfatase 2 (SULF2) in driving HCC angiogenesis. Sulf2-deficient mice (Sulf2 KO) exhibited resistance to diethylnitrosamine-induced HCC and did not develop metastases like wild-type mice (Sulf2 WT). The smaller and less numerous tumors formed in Sulf2 KO mice exhibited a markedly lower microvascular density. In human HCC cells, SULF2 overexpression increased endothelial proliferation, adhesion, chemotaxis, and tube formation in a paracrine fashion. Mechanistic analyses identified the extracellular matrix protein periostin (POSTN), a ligand of αvβ3/5 integrins, as an effector protein in SULF2-induced angiogenesis. POSTN silencing in HCC cells attenuated SULF2-induced angiogenesis and tumor growth in vivo. The TGFβ1/SMAD pathway was identified as a critical signaling axis between SULF2 and upregulation of POSTN transcription. In clinical HCC specimens, elevated levels of SULF2 correlated with increased microvascular density, POSTN levels, and relatively poorer patient survival. Together, our findings define an important axis controlling angiogenesis in HCC and a mechanistic foundation for rational drug development. Cancer Res; 77(3); 632–45. ©2016 AACR.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........23c13454228018c34202a7b0dab4ca96